Crossover investors help Generation Bio land $110M series C to expand non-viral gene therapy platform

Since raising its $100 million series B round in 2018, Generation Bio has developed a GMP-ready manufacturing process for its non-viral gene therapies and developed a way to target them to specific tissues. The company now plans to use its $110

Read the full 414 word article

User Sign In